Cardima Announces Completion of Ventricular Tachycardia Feasibility Trial With Positive Preliminary Results.

Business Editors

FREMONT, Calif.--(BUSINESS WIRE)--April 4, 2000

Cardima, Inc. (Nasdaq SC:CRDM) announced completion of its feasibility trial with the Therastream(TM) microcatheter, which resulted in positive preliminary results in treating patients with ventricular tachycardia (VT). VT is an arrhythmia that results in very rapid heart rates and affects more than 1,000,000 people in the United States alone.

Currently, VT is typically treated with anti-arrhythmic drugs or by implantation of an internal cardioverter defibrillator (ICD). Neither of these treatments cures the VT, merely dealing with the symptoms. Cardima is using radio frequency energy through the Therastream microcatheter to treat the diseased site.

Based on these results, the Company will ask the U. S. Food and Drug Administration (FDA) to expand the study.

Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those in such forward-looking statements. Potential risks and uncertainties include whether the Company will be able to complete clinical trials, gain necessary regulatory approvals and gain market acceptance for its products. Additional risks are set forth in Cardima's Annual Report on Form 10-K for December 31, 1999 filed with the Securities and Exchange Commission on March 30, 2000.